Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thomas, S. R.
Right arrow Articles by Saenger, E. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomas, S. R.
Right arrow Articles by Saenger, E. L.

Radiology, Vol 122, 731-737, Copyright © 1977 by Radiological Society of North America

ARTICLES

Quantitative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well-differentiated thyroid cancer

SR Thomas, HR Maxon, JG Kereiakes and EL Saenger

A quantitative technique is described which allows the physician to predict more accurately whether a recurrent or metastatic well- differentiated thyroid carcinoma is amenable to radioiodine-131 therapy or is better treated by other means. A calibrated uptake probe and scaler system is used to obtain conjugate view (i.e., diametrically opposed) counting rates for both the whole body and for any areas of abnormal uptake (lesion) at 24,48 annd 72 hours following the administration of 2 mCi 131l. Quantitative calculations accounting for patient attenuation, lesion size and geometrical factors then provide a determination of the lesion uptake as well as the effective half-life of 131l in the lesion. The radiation dose which would be delivered to the lesion by a given therapeutic amount of 131l may then be calculated to help determine the desirability of 131l treatment. The results of patient studies indicate the potential benefit of such quantitative evaluation.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
C. S. Bal, A. Kumar, and G. S. Pant
Radioiodine Dose for Remnant Ablation in Differentiated Thyroid Carcinoma: A Randomized Clinical Trial in 509 Patients
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1666 - 1673.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Lassmann, M. Luster, H. Hanscheid, and C. Reiners
Impact of 131I Diagnostic Activities on the Biokinetics of Thyroid Remnants
J. Nucl. Med., April 1, 2004; 45(4): 619 - 625.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. C. Sisson and J. E. Carey
Thyroid Carcinoma with High Levels of Function: Treatment with 131I
J. Nucl. Med., June 1, 2001; 42(6): 975 - 983.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. M. Kaptein, H. Levenson, M. E. Siegel, M. Gadallah, and M. Akmal
Radioiodine Dosimetry in Patients with End-Stage Renal Disease Receiving Continuous Ambulatory Peritoneal Dialysis Therapy
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3058 - 3064.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
M. C. Graham, H. I. Scher, G.-B. Liu, S. D-J. Yeh, T. Curley, F. Daghighian, S. J. Goldsmith, and S. M. Larson
Rhenium-186-labeled Hydroxyethylidene Diphosphonate Dosimetry and Dosing Guidelines for the Palliation of Skeletal Metastases from Androgen-independent Prostate Cancer
Clin. Cancer Res., June 1, 1999; 5(6): 1307 - 1318.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1977 by the Radiological Society of North America.